101 related articles for article (PubMed ID: 8540350)
1. Inhibitor-resistant mutants of the HIV-1 aspartic protease.
Korant BD
Adv Exp Med Biol; 1995; 362():407-11. PubMed ID: 8540350
[No Abstract] [Full Text] [Related]
2. A rapid and simple screening method for HIV-1 protease inhibitors using recombinant Escherichia coli.
Kaneto R; Kojima I; Shibamoto N; Nishida H; Okamoto R; Akagawa H; Mizuno S
J Antibiot (Tokyo); 1994 Apr; 47(4):492-5. PubMed ID: 8195050
[No Abstract] [Full Text] [Related]
3. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
[TBL] [Abstract][Full Text] [Related]
4. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.
Maschera B; Furfine E; Blair ED
J Virol; 1995 Sep; 69(9):5431-6. PubMed ID: 7636988
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site.
Sardana VV; Schlabach AJ; Graham P; Bush BL; Condra JH; Culberson JC; Gotlib L; Graham DJ; Kohl NE; LaFemina RL
Biochemistry; 1994 Mar; 33(8):2004-10. PubMed ID: 8117657
[TBL] [Abstract][Full Text] [Related]
6. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
Mahalingam B; Wang YF; Boross PI; Tozser J; Louis JM; Harrison RW; Weber IT
Eur J Biochem; 2004 Apr; 271(8):1516-24. PubMed ID: 15066177
[TBL] [Abstract][Full Text] [Related]
8. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.
Gulnik SV; Suvorov LI; Liu B; Yu B; Anderson B; Mitsuya H; Erickson JW
Biochemistry; 1995 Jul; 34(29):9282-7. PubMed ID: 7626598
[TBL] [Abstract][Full Text] [Related]
9. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.
Ala PJ; Huston EE; Klabe RM; Jadhav PK; Lam PY; Chang CH
Biochemistry; 1998 Oct; 37(43):15042-9. PubMed ID: 9790666
[TBL] [Abstract][Full Text] [Related]
10. Secondary structure and signal assignments of human-immunodeficiency-virus-1 protease complexed to a novel, structure-based inhibitor.
Yamazaki T; Nicholson LK; Torchia DA; Stahl SJ; Kaufman JD; Wingfield PT; Domaille PJ; Campbell-Burk S
Eur J Biochem; 1994 Jan; 219(1-2):707-12. PubMed ID: 8307036
[TBL] [Abstract][Full Text] [Related]
11. Predicting drug-resistant mutations of HIV protease.
Ishikita H; Warshel A
Angew Chem Int Ed Engl; 2008; 47(4):697-700. PubMed ID: 18058968
[No Abstract] [Full Text] [Related]
12. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
13. Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.
Sices HJ; Leusink MD; Pacheco A; Kristie TM
AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1249-55. PubMed ID: 11559424
[TBL] [Abstract][Full Text] [Related]
14. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
[TBL] [Abstract][Full Text] [Related]
15. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
17. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
[TBL] [Abstract][Full Text] [Related]
18. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
Ermolieff J; Lin X; Tang J
Biochemistry; 1997 Oct; 36(40):12364-70. PubMed ID: 9315877
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
[TBL] [Abstract][Full Text] [Related]
20. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
Garg R; Bhhatarai B
Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
